Melatonin Drugs Inhibit SARS-CoV-2 Entry into the Brain and Virus-induced Damage of Cerebral Small Vessels

Erika Cecon et al.

COVID-19 is a complex disease with short- and long-term respiratory, inflammatory and neurological symptoms that are triggered by the infection with SARS-CoV-2. Invasion of the brain by SARS-CoV-2 has been observed in humans and is postulated to be involved in post COVID condition. Brain infection is particularly pronounced in the K18-hACE2 mouse model of COVID-19. Here, we show that treatment of K18-hACE2 mice with melatonin and two melatonin-derived marketed drugs, agomelatine and ramelteon, prevent SARS-CoV-2 entry in the brain thereby reducing virus-induced damage of small cerebral vessels, immune cell infiltration and brain inflammation. Brain entry of SARS-CoV-2 through endothelial cells is prevented by melatonin through allosteric binding to human angiotensin-converting enzyme 2 (ACE2), which interferes with the cell entry receptor function of ACE2 for SARS-CoV-2. Our findings open new perspectives for the repurposing of melatonergic drugs in the prevention of brain infection by SARS-CoV-2 and COVID-19-related long-term neurological symptoms.

Latest articles

Byram W. Bridle … In response to a great question about a...
Vesanto Melina Soy has been the focus of considerable controversy. The roots...
Mark Messina … Isoflavones are classified as both phytoestrogens and selective estrogen...
BRMI … The lymphatic system lacks an organ that acts as a...
Jiacheng Huang et al. The extracellular matrix (ECM) is one of the...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!